ClinicalTrials.gg
RecruitingNCT07609914Updated Oct 14, 2026

A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

A Phase 4 interventional study of Rimegepant in Acute Treatment of Migraine, sponsored by Pfizer. Recruiting at 24 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 14, 2026Site recruiting status changedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
400
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Planned enrollment
20th of 32
400 · median 618
Started
2026
with 5 others
Phase 4
9 of 32
4 open now
Primary completion
2028-06
later than 8 of 14 live
Registered
27th of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 20th largest by planned enrollment, is one of 6 that started in 2026, is one of 9 in phase 4, reaches primary completion later than 8 of the 14 other live ones, and was the 27th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack.

The primary purpose of this study is to evaluate the safety and tolerability of redosing of rimegepant when taken for the acute treatment of a migraine attack, as it is possible that some patients may benefit from a second dose of rimegepant in this setting.

Read the detailed description

To evaluate the safety and tolerability of rimegepant 75 mg ODT when redosed due to residual pain or headache relapse

03

Conditions studied

  • Acute Treatment of Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible participants include adult participants aged 18 years of age or older with a minimum 1-year history of migraine (with or without aura) consistent with International Classification of Headache Disorders, 3rd Edition
  • Eligible participants must be currently using acute migraine treatment in accordance with the local label and have all of the following on average across the 12 weeks prior to the Screening Visit and, during the first 28 days of the observation phase (OP): (1) 6-14 monthly migraine days (MMDs); (2) \<15 monthly headache days (MHDs) (migraine or non-migraine); and (3) \<7 monthly non-migraine headache days.

Exclusion criteria

Exclusion:

  • Participants with headaches occurring ≥15 days per month (migraine or non-migraine) on average across the 12 weeks prior to the Screening Visit and ≥7 non-migraine headache days per month on average across the 12 weeks prior to the Screening Visit would not be eligible.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Rimegepant

    Participants will receive rimegepant 75 mg ODT to administer for the acute treatment of migraine attacks of moderate or severe headache pain intensity. A second rimegepant 75 mg ODT should be taken in the event that participants are not pain free at approximately 2 hours post initial dose OR upon headache relapse after initial pain freedom. The second dose should be taken within 24 hours of the initial dose. Participants will receive rimegepant over a 24 week period during the OLT phase. Participants may redose with rimegepant up to a maximum of 10 times per month (28 days) during the OLT phase.

    Drug: Rimegepant

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs), serious TEAEs, and TEAEs leading to study intervention discontinuation on treatment by average monthly redosing frequency over the entire OLT phase (<3, ≥3 to <6, ≥6 re-doses per month) and overall

    Time frame: Up to 6 months

  2. Incidence of LFT elevations, AST >3x ULN, alanine aminotransferase ALT >3x ULN, and total bilirubin >2x ULN on treatment by average monthly redosing frequency over the entire OLT phase (<3, ≥3 to <6, ≥6 re-doses per month) and overall

    Time frame: Up to 6 months

Secondary outcomes

  1. Percentage of rimegepant-redosed headache days with satisfaction with headache pain reduction over the entire OLT phase, based on a rating of 'Extremely satisfied' or 'Satisfied' for satisfaction with study intervention to reduce headache pain

    Time frame: Up to 6 months

  2. Percentage of rimegepant-redosed headache days with reduced impact on daily activities over the entire OLT phase, based on a rating of 'Very good' or 'Good' for the ability of study intervention to reduce the impact of headaches on daily activities

    Time frame: Up to 6 months

07

Study locations

19 of 24 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

Of 28 industry-sponsored phase 4 interventional studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's planned 24 months is below that.

Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion May 2028 → Jun 2028 and completion May 2028 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
May 27, 2026
StartActual
May 28, 2026
Primary completionEst.
Jun 7, 2028was May 2028
CompletionEst.
Jun 7, 2028was May 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added. 5 sites changed recruiting status (5 now recruiting)
Show 5 sites
  • Medstar Health - Department of Neurology · McLean, United StatesNot yet recruiting→Recruiting
  • Shaare Zedek Medical Center · Jerusalem, IsraelNot yet recruiting→Recruiting
  • Sourasky Medical Center · Tel Aviv, IsraelNot yet recruiting→Recruiting
  • AppleMedical Research Group, Inc. · Miami, United StatesNot yet recruiting→Recruiting
  • M3 Wake Research - Las Vegas Rainbow · Las Vegas, United StatesNot yet recruiting→Recruiting
Show 10 added (9 United States, 1 Israel)
  • Neuro-Pain Research Center · Fresno, United States
  • AppleMedical Research Group, Inc. · Miami, United States
  • Josephson Wallack Munshower Neurology · Indianapolis, United States
  • Minneapolis Clinic of Neurology - Burnsville Office · Burnsville, United States
  • Alliance Clinical Research Las Vegas (Excel Clinical Research) · Las Vegas, United States
  • M3 Wake Research - Las Vegas Rainbow · Las Vegas, United States
  • Red Star Research, LLC · Lake Jackson, United States
  • Cedar Crosse Research Center · Chicago, United States
  • Abington Neurological Associates · Abington, United States
  • Sheba Medical Center · Ramat Gan, Israel
across 2 updates, Sep 25, 2026 – Oct 14, 2026
Primary completion
May 15, 2028→Jun 7, 2028
Sep 25, 2026
Study completion
May 15, 2028→Jun 7, 2028
Sep 25, 2026
Show all 2 updates
  1. Oct 14, 2026
    3 sites added. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • AppleMedical Research Group, Inc. · Miami, United StatesNot yet recruiting→Recruiting
    • M3 Wake Research - Las Vegas Rainbow · Las Vegas, United StatesNot yet recruiting→Recruiting
    Show 3 added (2 United States, 1 Israel)
    • Cedar Crosse Research Center · Chicago, United States
    • Abington Neurological Associates · Abington, United States
    • Sheba Medical Center · Ramat Gan, Israel
    + 1 other change: verification date
  2. Sep 25, 2026
    7 sites added. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Medstar Health - Department of Neurology · McLean, United StatesNot yet recruiting→Recruiting
    • Shaare Zedek Medical Center · Jerusalem, IsraelNot yet recruiting→Recruiting
    • Sourasky Medical Center · Tel Aviv, IsraelNot yet recruiting→Recruiting
    Show 7 added (7 United States)
    • Neuro-Pain Research Center · Fresno, United States
    • AppleMedical Research Group, Inc. · Miami, United States
    • Josephson Wallack Munshower Neurology · Indianapolis, United States
    • Minneapolis Clinic of Neurology - Burnsville Office · Burnsville, United States
    • Alliance Clinical Research Las Vegas (Excel Clinical Research) · Las Vegas, United States
    • M3 Wake Research - Las Vegas Rainbow · Las Vegas, United States
    • Red Star Research, LLC · Lake Jackson, United States
    Primary completion May 15, 2028→Jun 7, 2028
    Study completion May 15, 2028→Jun 7, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07609914
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 27, 2026
Start date
May 28, 2026
Primary completion
Jun 7, 2028 (estimated)
Completion
Jun 7, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion